TW200804313A - Triazole compounds that modulate HSP90 activity - Google Patents

Info

Publication number

TW200804313A

TW200804313A TW096118677A TW96118677A TW200804313A TW 200804313 A TW200804313 A TW 200804313A TW 096118677 A TW096118677 A TW 096118677A TW 96118677 A TW96118677 A TW 96118677A TW 200804313 A TW200804313 A TW 200804313A

Authority

TW

Taiwan

Prior art keywords

optionally substituted

group

compound

nr10rn

nr7c

Prior art date

2006-05-25

Links

• Espacenet
• Global Dossier
• Discuss

• -1 Triazole compounds Chemical class 0.000 title claims abstract description 321
• 230000000694 effects Effects 0.000 title abstract description 50
• 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 title abstract description 27
• 101710113864 Heat shock protein 90 Proteins 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 579
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 120
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 83
• 201000011510 cancer Diseases 0.000 claims abstract description 76
• 238000000034 method Methods 0.000 claims abstract description 32
• 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
• 125000001072 heteroaryl group Chemical group 0.000 claims description 147
• 125000000217 alkyl group Chemical group 0.000 claims description 134
• 125000000623 heterocyclic group Chemical group 0.000 claims description 125
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 100
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 96
• 125000003107 substituted aryl group Chemical group 0.000 claims description 96
• 229910052757 nitrogen Inorganic materials 0.000 claims description 83
• 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 76
• 210000004027 cell Anatomy 0.000 claims description 75
• 150000003839 salts Chemical class 0.000 claims description 72
• 125000003545 alkoxy group Chemical group 0.000 claims description 70
• 125000004426 substituted alkynyl group Chemical group 0.000 claims description 66
• 125000001424 substituent group Chemical group 0.000 claims description 65
• 229940002612 prodrug Drugs 0.000 claims description 64
• 239000000651 prodrug Substances 0.000 claims description 64
• 239000012453 solvate Substances 0.000 claims description 64
• 125000005017 substituted alkenyl group Chemical group 0.000 claims description 64
• 229910052799 carbon Inorganic materials 0.000 claims description 62
• 125000000547 substituted alkyl group Chemical group 0.000 claims description 62
• 229960001755 resorcinol Drugs 0.000 claims description 60
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 57
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 52
• 125000001188 haloalkyl group Chemical group 0.000 claims description 52
• 150000001721 carbon Chemical group 0.000 claims description 51
• 239000003814 drug Substances 0.000 claims description 51
• 125000003118 aryl group Chemical group 0.000 claims description 49
• YCIMNLLNPGFGHC-UHFFFAOYSA-N o-dihydroxy-benzene Natural products OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 49
• GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 46
• 125000004475 heteroaralkyl group Chemical group 0.000 claims description 41
• 125000004076 pyridyl group Chemical group 0.000 claims description 39
• 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 38
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 38
• 229910052736 halogen Inorganic materials 0.000 claims description 37
• 150000002367 halogens Chemical class 0.000 claims description 37
• 238000011282 treatment Methods 0.000 claims description 36
• 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 35
• 125000003342 alkenyl group Chemical group 0.000 claims description 34
• 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 34
• 208000032839 leukemia Diseases 0.000 claims description 34
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 32
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 32
• 108090000623 proteins and genes Proteins 0.000 claims description 32
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 31
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 29
• 241000282414 Homo sapiens Species 0.000 claims description 28
• 150000003573 thiols Chemical class 0.000 claims description 27
• 230000002062 proliferating effect Effects 0.000 claims description 26
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 25
• 239000013078 crystal Substances 0.000 claims description 25
• 125000000304 alkynyl group Chemical group 0.000 claims description 24
• 102000004169 proteins and genes Human genes 0.000 claims description 22
• 229910052717 sulfur Inorganic materials 0.000 claims description 22
• 229940079593 drug Drugs 0.000 claims description 21
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 20
• 125000004432 carbon atom Chemical group C* 0.000 claims description 20
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 20
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
• 206010036790 Productive cough Diseases 0.000 claims description 19
• 210000003802 sputum Anatomy 0.000 claims description 19
• 208000024794 sputum Diseases 0.000 claims description 19
• 230000015556 catabolic process Effects 0.000 claims description 18
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
• 208000015181 infectious disease Diseases 0.000 claims description 18
• 210000003296 saliva Anatomy 0.000 claims description 18
• 125000004414 alkyl thio group Chemical group 0.000 claims description 17
• 238000006731 degradation reaction Methods 0.000 claims description 17
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 17
• 210000004369 blood Anatomy 0.000 claims description 16
• 239000008280 blood Substances 0.000 claims description 16
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 16
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 16
• 229940124597 therapeutic agent Drugs 0.000 claims description 16
• KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 15
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 15
• 238000002360 preparation method Methods 0.000 claims description 15
• 125000003396 thiol group Chemical group [H]S* 0.000 claims description 15
• 206010025323 Lymphomas Diseases 0.000 claims description 14
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims description 14
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims description 14
• 210000001519 tissue Anatomy 0.000 claims description 14
• 125000005605 benzo group Chemical group 0.000 claims description 13
• 230000001684 chronic effect Effects 0.000 claims description 13
• 125000004438 haloalkoxy group Chemical group 0.000 claims description 13
• 125000005842 heteroatom Chemical group 0.000 claims description 13
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
• 125000002541 furyl group Chemical group 0.000 claims description 12
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 12
• 229910052760 oxygen Inorganic materials 0.000 claims description 12
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
• 230000004968 inflammatory condition Effects 0.000 claims description 11
• 239000001301 oxygen Substances 0.000 claims description 11
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 11
• 125000002947 alkylene group Chemical group 0.000 claims description 10
• 125000004429 atom Chemical group 0.000 claims description 10
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 10
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 10
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 10
• 208000026278 immune system disease Diseases 0.000 claims description 10
• 229960005181 morphine Drugs 0.000 claims description 10
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
• 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims description 9
• 241000124008 Mammalia Species 0.000 claims description 9
• 125000005647 linker group Chemical group 0.000 claims description 9
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 9
• 125000002971 oxazolyl group Chemical group 0.000 claims description 9
• 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 8
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 8
• 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims description 8
• 150000002009 diols Chemical class 0.000 claims description 8
• 239000000463 material Substances 0.000 claims description 8
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 8
• 150000001345 alkine derivatives Chemical group 0.000 claims description 7
• 125000003282 alkyl amino group Chemical group 0.000 claims description 7
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims description 7
• 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims description 7
• 125000005874 benzothiadiazolyl group Chemical group 0.000 claims description 7
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 7
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 7
• 125000004122 cyclic group Chemical group 0.000 claims description 7
• 230000006378 damage Effects 0.000 claims description 7
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
• 230000003412 degenerative effect Effects 0.000 claims description 7
• 125000005956 isoquinolyl group Chemical group 0.000 claims description 7
• 230000002265 prevention Effects 0.000 claims description 7
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 7
• 229910052707 ruthenium Inorganic materials 0.000 claims description 7
• 230000009385 viral infection Effects 0.000 claims description 7
• UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Natural products C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims description 6
• 108091008648 NR7C Proteins 0.000 claims description 6
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 6
• 208000036142 Viral infection Diseases 0.000 claims description 6
• 150000001716 carbazoles Chemical group 0.000 claims description 6
• ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 claims description 6
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 6
• 125000005843 halogen group Chemical group 0.000 claims description 6
• 125000005945 imidazopyridyl group Chemical group 0.000 claims description 6
• 201000006747 infectious mononucleosis Diseases 0.000 claims description 6
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
• 150000002923 oximes Chemical class 0.000 claims description 6
• 239000002904 solvent Substances 0.000 claims description 6
• 238000006467 substitution reaction Methods 0.000 claims description 6
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 5
• WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 5
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 5
• 235000007164 Oryza sativa Nutrition 0.000 claims description 5
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 5
• 150000001335 aliphatic alkanes Chemical class 0.000 claims description 5
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 5
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 5
• 208000014674 injury Diseases 0.000 claims description 5
• 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 5
• 235000009566 rice Nutrition 0.000 claims description 5
• 239000002689 soil Substances 0.000 claims description 5
• 125000001544 thienyl group Chemical group 0.000 claims description 5
• 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 claims description 4
• 101100495922 Arabidopsis thaliana CHR28 gene Proteins 0.000 claims description 4
• 101100439665 Arabidopsis thaliana SWI2 gene Proteins 0.000 claims description 4
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
• 208000030852 Parasitic disease Diseases 0.000 claims description 4
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims description 4
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
• 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 claims description 4
• 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 150000002429 hydrazines Chemical class 0.000 claims description 4
• 150000002460 imidazoles Chemical class 0.000 claims description 4
• 210000001165 lymph node Anatomy 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• 229910052698 phosphorus Inorganic materials 0.000 claims description 4
• 150000003222 pyridines Chemical class 0.000 claims description 4
• 201000006845 reticulosarcoma Diseases 0.000 claims description 4
• 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 4
• 238000000926 separation method Methods 0.000 claims description 4
• 229910021653 sulphate ion Inorganic materials 0.000 claims description 4
• 125000001425 triazolyl group Chemical group 0.000 claims description 4
• SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 claims description 3
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
• 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 3
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
• XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 3
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 3
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 3
• 244000170916 Paeonia officinalis Species 0.000 claims description 3
• 235000006484 Paeonia officinalis Nutrition 0.000 claims description 3
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
• 208000007452 Plasmacytoma Diseases 0.000 claims description 3
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 3
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
• 150000008366 benzophenones Chemical class 0.000 claims description 3
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
• 229910052805 deuterium Inorganic materials 0.000 claims description 3
• 125000005265 dialkylamine group Chemical group 0.000 claims description 3
• 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims description 3
• 201000000564 macroglobulinemia Diseases 0.000 claims description 3
• 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 3
• 208000021937 marginal zone lymphoma Diseases 0.000 claims description 3
• NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims description 3
• 125000000335 thiazolyl group Chemical group 0.000 claims description 3
• 230000009466 transformation Effects 0.000 claims description 3
• PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical class C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 claims description 2
• LYXCJGJSIWFKHZ-UHFFFAOYSA-N 4-phenylbenzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1C1=CC=CC=C1 LYXCJGJSIWFKHZ-UHFFFAOYSA-N 0.000 claims description 2
• 239000005711 Benzoic acid Substances 0.000 claims description 2
• ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
• 208000027418 Wounds and injury Diseases 0.000 claims description 2
• PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims description 2
• 150000004056 anthraquinones Chemical class 0.000 claims description 2
• 235000010233 benzoic acid Nutrition 0.000 claims description 2
• 239000012965 benzophenone Substances 0.000 claims description 2
• 239000004305 biphenyl Substances 0.000 claims description 2
• 238000001354 calcination Methods 0.000 claims description 2
• 125000006612 decyloxy group Chemical group 0.000 claims description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
• 230000003325 follicular Effects 0.000 claims description 2
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
• 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
• 125000002757 morpholinyl group Chemical group 0.000 claims description 2
• 230000002093 peripheral effect Effects 0.000 claims description 2
• 239000002243 precursor Substances 0.000 claims description 2
• 150000003248 quinolines Chemical group 0.000 claims description 2
• 230000001629 suppression Effects 0.000 claims description 2
• 239000002023 wood Substances 0.000 claims description 2
• 230000008774 maternal effect Effects 0.000 claims 6
• 241000209094 Oryza Species 0.000 claims 4
• 150000002576 ketones Chemical class 0.000 claims 4
• 150000003557 thiazoles Chemical class 0.000 claims 4
• 230000000007 visual effect Effects 0.000 claims 4
• 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 3
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 3
• 241000282326 Felis catus Species 0.000 claims 3
• 150000003851 azoles Chemical class 0.000 claims 3
• 230000001939 inductive effect Effects 0.000 claims 3
• 239000000825 pharmaceutical preparation Substances 0.000 claims 3
• 229940127557 pharmaceutical product Drugs 0.000 claims 3
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
• KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical class N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 claims 2
• 206010039424 Salivary hypersecretion Diseases 0.000 claims 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
• 150000001555 benzenes Chemical class 0.000 claims 2
• RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 claims 2
• 125000005549 heteroarylene group Chemical group 0.000 claims 2
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
• 125000002883 imidazolyl group Chemical class 0.000 claims 2
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 2
• 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 2
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
• 150000003233 pyrroles Chemical class 0.000 claims 2
• 208000026451 salivation Diseases 0.000 claims 2
• UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 claims 1
• XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 claims 1
• FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 claims 1
• FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical class C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 1
• KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 claims 1
• APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical group N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 claims 1
• YHIKXGASRRAEIA-UHFFFAOYSA-N 1h-1,2,4-triazol-5-ylcarbamic acid Chemical compound OC(=O)NC1=NC=NN1 YHIKXGASRRAEIA-UHFFFAOYSA-N 0.000 claims 1
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
• VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 claims 1
• MDKNXOUZKIPYIW-UHFFFAOYSA-N 3-[2,5-dihydroxy-4-(hydroxymethyl)phenyl]-4-naphthalen-1-yl-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CO)=CC(O)=C1C1=NN=C(S)N1C1=CC=CC2=CC=CC=C12 MDKNXOUZKIPYIW-UHFFFAOYSA-N 0.000 claims 1
• FCLPHKYGCXZMQJ-UHFFFAOYSA-N 3-[5-[2-(3-fluorophenyl)ethyl]-2,4-dihydroxyphenyl]-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one Chemical compound C=1C=C2N(C)C=CC2=CC=1N1C(O)=NN=C1C(C(=CC=1O)O)=CC=1CCC1=CC=CC(F)=C1 FCLPHKYGCXZMQJ-UHFFFAOYSA-N 0.000 claims 1
• XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 claims 1
• GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 claims 1
• VGMJYYDKPUPTID-UHFFFAOYSA-N 4-ethylbenzene-1,3-diol Chemical compound CCC1=CC=C(O)C=C1O VGMJYYDKPUPTID-UHFFFAOYSA-N 0.000 claims 1
• WGCNRWMDVIEWHG-UHFFFAOYSA-N 5-nonyl-1h-1,2,4-triazole Chemical compound CCCCCCCCCC1=NC=NN1 WGCNRWMDVIEWHG-UHFFFAOYSA-N 0.000 claims 1
• KCOYLRXCNKJSSC-UHFFFAOYSA-N 9h-carbazole Chemical class C1=CC=C2C3=CC=CC=C3NC2=C1.C1=CC=C2C3=CC=CC=C3NC2=C1 KCOYLRXCNKJSSC-UHFFFAOYSA-N 0.000 claims 1
• FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical class C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 claims 1
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
• 206010011224 Cough Diseases 0.000 claims 1
• 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 1
• CDSKIAYJECTPCP-UHFFFAOYSA-N N1C(NC2=C1C=CC=C2)=O.C2=CC=CC=1C3=CC=CC=C3CC21 Chemical compound N1C(NC2=C1C=CC=C2)=O.C2=CC=CC=1C3=CC=CC=C3CC21 CDSKIAYJECTPCP-UHFFFAOYSA-N 0.000 claims 1
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical class C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 1
• 241000239226 Scorpiones Species 0.000 claims 1
• 241000207929 Scutellaria Species 0.000 claims 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
• IDKYLRUSKCDRNJ-UHFFFAOYSA-N [5-(5-ethyl-2,4-dihydroxyphenyl)-4-quinolin-5-yl-1,2,4-triazol-3-yl]urea Chemical compound C1=C(O)C(CC)=CC(C=2N(C(NC(N)=O)=NN=2)C=2C3=CC=CN=C3C=CC=2)=C1O IDKYLRUSKCDRNJ-UHFFFAOYSA-N 0.000 claims 1
• NIPKWHDWQKDKTL-UHFFFAOYSA-N [O].C1CC1 Chemical compound [O].C1CC1 NIPKWHDWQKDKTL-UHFFFAOYSA-N 0.000 claims 1
• YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 claims 1
• 229960005164 acesulfame Drugs 0.000 claims 1
• 150000001336 alkenes Chemical group 0.000 claims 1
• 239000011425 bamboo Substances 0.000 claims 1
• JWZWHTQLMYAMJL-UHFFFAOYSA-N benzene isoquinoline Chemical class C1=CC=CC=C1.C1=NC=CC2=CC=CC=C12 JWZWHTQLMYAMJL-UHFFFAOYSA-N 0.000 claims 1
• WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical group C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 claims 1
• 150000001556 benzimidazoles Chemical class 0.000 claims 1
• 229940049706 benzodiazepine Drugs 0.000 claims 1
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 1
• SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 1
• 150000007657 benzothiazepines Chemical class 0.000 claims 1
• KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
• 238000003776 cleavage reaction Methods 0.000 claims 1
• 229940125936 compound 42 Drugs 0.000 claims 1
• IZJPDMAOXFNGNK-UHFFFAOYSA-N cyclopenta[d]triazole Chemical compound N1=NC2=CC=CC2=N1 IZJPDMAOXFNGNK-UHFFFAOYSA-N 0.000 claims 1
• 150000001983 dialkylethers Chemical class 0.000 claims 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
• AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
• 150000002366 halogen compounds Chemical class 0.000 claims 1
• 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 claims 1
• 150000004693 imidazolium salts Chemical class 0.000 claims 1
• 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
• 150000002475 indoles Chemical class 0.000 claims 1
• 229920005610 lignin Polymers 0.000 claims 1
• 230000001926 lymphatic effect Effects 0.000 claims 1
• 235000012054 meals Nutrition 0.000 claims 1
• 239000008267 milk Substances 0.000 claims 1
• DYGBNAYFDZEYBA-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-n-[(4-oxo-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(CC(=O)N(CC2CC2)CC=2NC(=O)C=3COCCC=3N=2)CC1 DYGBNAYFDZEYBA-UHFFFAOYSA-N 0.000 claims 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
• 150000002829 nitrogen Chemical class 0.000 claims 1
• 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• 108020004017 nuclear receptors Proteins 0.000 claims 1
• QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical class C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 claims 1
• 125000003544 oxime group Chemical group 0.000 claims 1
• DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims 1
• 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
• 150000004032 porphyrins Chemical class 0.000 claims 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
• ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 1
• 150000004944 pyrrolopyrimidines Chemical class 0.000 claims 1
• 125000005493 quinolyl group Chemical group 0.000 claims 1
• 230000007017 scission Effects 0.000 claims 1
• PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical group C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims 1
• VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical class S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 claims 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
• 239000000829 suppository Substances 0.000 claims 1
• 238000003419 tautomerization reaction Methods 0.000 claims 1
• 150000003536 tetrazoles Chemical class 0.000 claims 1
• KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 1
• 229960001082 trimethoprim Drugs 0.000 claims 1
• SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims 1
• 239000000052 vinegar Substances 0.000 claims 1
• 235000021419 vinegar Nutrition 0.000 claims 1
• 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 abstract description 26
• 239000000203 mixture Chemical class 0.000 abstract description 18
• 230000003463 hyperproliferative effect Effects 0.000 abstract description 4
• 230000035772 mutation Effects 0.000 description 60
• 201000010099 disease Diseases 0.000 description 51
• 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 38
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 38
• KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 36
• 101100381978 Mus musculus Braf gene Proteins 0.000 description 36
• 239000002585 base Substances 0.000 description 34
• 108060006698 EGF receptor Proteins 0.000 description 32
• 102000001301 EGF receptor Human genes 0.000 description 30
• 208000035475 disorder Diseases 0.000 description 28
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 24
• 239000002246 antineoplastic agent Substances 0.000 description 23
• 108091000080 Phosphotransferase Proteins 0.000 description 21
• 230000004913 activation Effects 0.000 description 21
• 102000020233 phosphotransferase Human genes 0.000 description 21
• 238000011161 development Methods 0.000 description 20
• 230000018109 developmental process Effects 0.000 description 20
• 235000018102 proteins Nutrition 0.000 description 20
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 19
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 19
• 239000000126 substance Substances 0.000 description 16
• 230000003213 activating effect Effects 0.000 description 15
• 238000002560 therapeutic procedure Methods 0.000 description 15
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 14
• 208000024891 symptom Diseases 0.000 description 14
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 13
• 208000023275 Autoimmune disease Diseases 0.000 description 13
• 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 13
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 13
• 238000006366 phosphorylation reaction Methods 0.000 description 13
• 102000005962 receptors Human genes 0.000 description 13
• 108020003175 receptors Proteins 0.000 description 13
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 12
• 230000014509 gene expression Effects 0.000 description 12
• 230000005764 inhibitory process Effects 0.000 description 12
• 230000026731 phosphorylation Effects 0.000 description 12
• 230000004083 survival effect Effects 0.000 description 12
• 206010006187 Breast cancer Diseases 0.000 description 11
• 208000026310 Breast neoplasm Diseases 0.000 description 11
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 11
• 206010057190 Respiratory tract infections Diseases 0.000 description 11
• 208000005718 Stomach Neoplasms Diseases 0.000 description 11
• 239000002253 acid Substances 0.000 description 11
• 230000027455 binding Effects 0.000 description 11
• 206010017758 gastric cancer Diseases 0.000 description 11
• 201000011549 stomach cancer Diseases 0.000 description 11
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 10
• 206010061218 Inflammation Diseases 0.000 description 10
• 206010039491 Sarcoma Diseases 0.000 description 10
• 125000000539 amino acid group Chemical group 0.000 description 10
• PKWIYNIDEDLDCJ-UHFFFAOYSA-N guanazole Chemical compound NC1=NNC(N)=N1 PKWIYNIDEDLDCJ-UHFFFAOYSA-N 0.000 description 10
• 230000004054 inflammatory process Effects 0.000 description 10
• 239000012528 membrane Substances 0.000 description 10
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 10
• 230000037361 pathway Effects 0.000 description 10
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 10
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 10
• 230000001105 regulatory effect Effects 0.000 description 10
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 9
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 9
• 206010041067 Small cell lung cancer Diseases 0.000 description 9
• 230000004663 cell proliferation Effects 0.000 description 9
• 229940127089 cytotoxic agent Drugs 0.000 description 9
• 230000000069 prophylactic effect Effects 0.000 description 9
• 102000016914 ras Proteins Human genes 0.000 description 9
• 208000000587 small cell lung carcinoma Diseases 0.000 description 9
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 9
• 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 8
• 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 8
• 206010009944 Colon cancer Diseases 0.000 description 8
• 241000222722 Leishmania <genus> Species 0.000 description 8
• 206010033128 Ovarian cancer Diseases 0.000 description 8
• 206010061535 Ovarian neoplasm Diseases 0.000 description 8
• 230000002159 abnormal effect Effects 0.000 description 8
• 230000001154 acute effect Effects 0.000 description 8
• 150000001412 amines Chemical class 0.000 description 8
• 230000006907 apoptotic process Effects 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 102000037865 fusion proteins Human genes 0.000 description 8
• 108020001507 fusion proteins Proteins 0.000 description 8
• 230000002757 inflammatory effect Effects 0.000 description 8
• 239000003446 ligand Substances 0.000 description 8
• 210000004379 membrane Anatomy 0.000 description 8
• 230000002018 overexpression Effects 0.000 description 8
• 210000003491 skin Anatomy 0.000 description 8
• 208000011580 syndromic disease Diseases 0.000 description 8
• AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 7
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 206010018338 Glioma Diseases 0.000 description 7
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
• 241000700605 Viruses Species 0.000 description 7
• 230000033115 angiogenesis Effects 0.000 description 7
• 210000000349 chromosome Anatomy 0.000 description 7
• 229940088598 enzyme Drugs 0.000 description 7
• 230000012010 growth Effects 0.000 description 7
• 210000000987 immune system Anatomy 0.000 description 7
• 229920006395 saturated elastomer Polymers 0.000 description 7
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 6
• 208000005623 Carcinogenesis Diseases 0.000 description 6
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 6
• 208000032612 Glial tumor Diseases 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
• 210000001744 T-lymphocyte Anatomy 0.000 description 6
• 235000001014 amino acid Nutrition 0.000 description 6
• 150000001413 amino acids Chemical class 0.000 description 6
• 229940041181 antineoplastic drug Drugs 0.000 description 6
• 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 6
• 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 6
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
• 230000036952 cancer formation Effects 0.000 description 6
• 231100000504 carcinogenesis Toxicity 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 238000002512 chemotherapy Methods 0.000 description 6
• 208000029742 colonic neoplasm Diseases 0.000 description 6
• 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 6
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• 238000010837 poor prognosis Methods 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 230000035755 proliferation Effects 0.000 description 6
• 102200055464 rs113488022 Human genes 0.000 description 6
• 230000005945 translocation Effects 0.000 description 6
• 230000002792 vascular Effects 0.000 description 6
• 201000009030 Carcinoma Diseases 0.000 description 5
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 5
• 102000003676 Glucocorticoid Receptors Human genes 0.000 description 5
• 108090000079 Glucocorticoid Receptors Proteins 0.000 description 5
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 5
• 102000043136 MAP kinase family Human genes 0.000 description 5
• 108091054455 MAP kinase family Proteins 0.000 description 5
• 101150105382 MET gene Proteins 0.000 description 5
• 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 5
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 5
• 108700020796 Oncogene Proteins 0.000 description 5
• 241000235648 Pichia Species 0.000 description 5
• 208000006265 Renal cell carcinoma Diseases 0.000 description 5
• 102000040945 Transcription factor Human genes 0.000 description 5
• 108091023040 Transcription factor Proteins 0.000 description 5
• 230000005856 abnormality Effects 0.000 description 5
• 208000009956 adenocarcinoma Diseases 0.000 description 5
• 229940024606 amino acid Drugs 0.000 description 5
• 230000003321 amplification Effects 0.000 description 5
• 229940124650 anti-cancer therapies Drugs 0.000 description 5
• 238000011319 anticancer therapy Methods 0.000 description 5
• 208000010668 atopic eczema Diseases 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 125000000524 functional group Chemical group 0.000 description 5
• 230000001976 improved effect Effects 0.000 description 5
• 210000003734 kidney Anatomy 0.000 description 5
• 206010025135 lupus erythematosus Diseases 0.000 description 5
• 230000003211 malignant effect Effects 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 238000003199 nucleic acid amplification method Methods 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 description 5
• 230000019491 signal transduction Effects 0.000 description 5
• 230000009885 systemic effect Effects 0.000 description 5
• 229950007866 tanespimycin Drugs 0.000 description 5
• AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 5
• NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
• 206010000830 Acute leukaemia Diseases 0.000 description 4
• 206010027654 Allergic conditions Diseases 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 208000011231 Crohn disease Diseases 0.000 description 4
• 201000004624 Dermatitis Diseases 0.000 description 4
• 206010012735 Diarrhoea Diseases 0.000 description 4
• 101150039808 Egfr gene Proteins 0.000 description 4
• 201000009273 Endometriosis Diseases 0.000 description 4
• 206010015150 Erythema Diseases 0.000 description 4
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 4
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 4
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
• 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 4
• 206010027476 Metastases Diseases 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
• 108010029485 Protein Isoforms Proteins 0.000 description 4
• 102000001708 Protein Isoforms Human genes 0.000 description 4
• 102000001253 Protein Kinase Human genes 0.000 description 4
• 108091008611 Protein Kinase B Proteins 0.000 description 4
• 201000004681 Psoriasis Diseases 0.000 description 4
• 241000235070 Saccharomyces Species 0.000 description 4
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
• 206010052779 Transplant rejections Diseases 0.000 description 4
• 208000025865 Ulcer Diseases 0.000 description 4
• 206010046851 Uveitis Diseases 0.000 description 4
• 230000000172 allergic effect Effects 0.000 description 4
• 208000006673 asthma Diseases 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 210000004556 brain Anatomy 0.000 description 4
• 238000006471 dimerization reaction Methods 0.000 description 4
• 108700021358 erbB-1 Genes Proteins 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• 108700014844 flt3 ligand Proteins 0.000 description 4
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
• 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 4
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
• 229930195733 hydrocarbon Natural products 0.000 description 4
• 206010020718 hyperplasia Diseases 0.000 description 4
• 229960002411 imatinib Drugs 0.000 description 4
• 230000006872 improvement Effects 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 208000027866 inflammatory disease Diseases 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 201000007270 liver cancer Diseases 0.000 description 4
• 208000014018 liver neoplasm Diseases 0.000 description 4
• 208000003747 lymphoid leukemia Diseases 0.000 description 4
• 238000012423 maintenance Methods 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 201000001441 melanoma Diseases 0.000 description 4
• 230000009401 metastasis Effects 0.000 description 4
• 125000002950 monocyclic group Chemical group 0.000 description 4
• 208000025113 myeloid leukemia Diseases 0.000 description 4
• 102000027450 oncoproteins Human genes 0.000 description 4
• 108091008819 oncoproteins Proteins 0.000 description 4
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
• 125000003367 polycyclic group Chemical group 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 125000006239 protecting group Chemical group 0.000 description 4
• 108060006633 protein kinase Proteins 0.000 description 4
• 230000035939 shock Effects 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
• 206010041823 squamous cell carcinoma Diseases 0.000 description 4
• 210000000130 stem cell Anatomy 0.000 description 4
• 239000011593 sulfur Substances 0.000 description 4
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 3
• RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 3
• 201000001320 Atherosclerosis Diseases 0.000 description 3
• 208000004736 B-Cell Leukemia Diseases 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 241000722885 Brettanomyces Species 0.000 description 3
• 206010006448 Bronchiolitis Diseases 0.000 description 3
• 241000282465 Canis Species 0.000 description 3
• 244000025254 Cannabis sativa Species 0.000 description 3
• 239000004215 Carbon black (E152) Substances 0.000 description 3
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
• 206010009900 Colitis ulcerative Diseases 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
• 206010012689 Diabetic retinopathy Diseases 0.000 description 3
• 208000004232 Enteritis Diseases 0.000 description 3
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• 206010021143 Hypoxia Diseases 0.000 description 3
• 208000007766 Kaposi sarcoma Diseases 0.000 description 3
• 208000019693 Lung disease Diseases 0.000 description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
• 208000009905 Neurofibromatoses Diseases 0.000 description 3
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
• 102000004422 Phospholipase C gamma Human genes 0.000 description 3
• 108010056751 Phospholipase C gamma Proteins 0.000 description 3
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
• 208000000389 T-cell leukemia Diseases 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 3
• 201000006704 Ulcerative Colitis Diseases 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 239000013566 allergen Substances 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• 230000003115 biocidal effect Effects 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 210000001185 bone marrow Anatomy 0.000 description 3
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
• 230000024245 cell differentiation Effects 0.000 description 3
• 208000006990 cholangiocarcinoma Diseases 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 230000006552 constitutive activation Effects 0.000 description 3
• 230000007850 degeneration Effects 0.000 description 3
• 231100000321 erythema Toxicity 0.000 description 3
• 201000004101 esophageal cancer Diseases 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 239000007789 gas Substances 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 230000036737 immune function Effects 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 201000001371 inclusion conjunctivitis Diseases 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 229940084651 iressa Drugs 0.000 description 3
• 206010023332 keratitis Diseases 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 201000005202 lung cancer Diseases 0.000 description 3
• 208000020816 lung neoplasm Diseases 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 208000002780 macular degeneration Diseases 0.000 description 3
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
• 230000001394 metastastic effect Effects 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 125000001624 naphthyl group Chemical group 0.000 description 3
• 201000008383 nephritis Diseases 0.000 description 3
• 201000004931 neurofibromatosis Diseases 0.000 description 3
• 201000002528 pancreatic cancer Diseases 0.000 description 3
• 208000008443 pancreatic carcinoma Diseases 0.000 description 3
• 201000010279 papillary renal cell carcinoma Diseases 0.000 description 3
• 238000004393 prognosis Methods 0.000 description 3
• ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 3
• 229960000885 rifabutin Drugs 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 206010044325 trachoma Diseases 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• 231100000397 ulcer Toxicity 0.000 description 3
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
• 230000029663 wound healing Effects 0.000 description 3
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
• 150000000185 1,3-diols Chemical class 0.000 description 2
• FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 description 2
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 101150019464 ARAF gene Proteins 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 102100032187 Androgen receptor Human genes 0.000 description 2
• 101150049556 Bcr gene Proteins 0.000 description 2
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
• 206010005003 Bladder cancer Diseases 0.000 description 2
• 244000027711 Brettanomyces bruxellensis Species 0.000 description 2
• 108091007381 CBL proteins Proteins 0.000 description 2
• 101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 description 2
• 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
• 241000222178 Candida tropicalis Species 0.000 description 2
• 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
• 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
• 241000700199 Cavia porcellus Species 0.000 description 2
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
• 230000004544 DNA amplification Effects 0.000 description 2
• 241000235036 Debaryomyces hansenii Species 0.000 description 2
• 101100289061 Drosophila melanogaster lili gene Proteins 0.000 description 2
• 206010058314 Dysplasia Diseases 0.000 description 2
• 101150029707 ERBB2 gene Proteins 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 102400001368 Epidermal growth factor Human genes 0.000 description 2
• 101800003838 Epidermal growth factor Proteins 0.000 description 2
• 102100038595 Estrogen receptor Human genes 0.000 description 2
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
• 239000005977 Ethylene Substances 0.000 description 2
• 208000004262 Food Hypersensitivity Diseases 0.000 description 2
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
• JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 2
• 206010064571 Gene mutation Diseases 0.000 description 2
• 208000034951 Genetic Translocation Diseases 0.000 description 2
• 208000010412 Glaucoma Diseases 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 102000009465 Growth Factor Receptors Human genes 0.000 description 2
• 108010009202 Growth Factor Receptors Proteins 0.000 description 2
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
• 102100026973 Heat shock protein 75 kDa, mitochondrial Human genes 0.000 description 2
• 102220553470 Hepatocyte growth factor receptor_Y1230C_mutation Human genes 0.000 description 2
• 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 2
• 208000017604 Hodgkin disease Diseases 0.000 description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
• 101000825399 Homo sapiens SHC-transforming protein 1 Proteins 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 208000006877 Insect Bites and Stings Diseases 0.000 description 2
• 241000710842 Japanese encephalitis virus Species 0.000 description 2
• 108010044023 Ki-1 Antigen Proteins 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• 206010023421 Kidney fibrosis Diseases 0.000 description 2
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
• 206010023927 Lassa fever Diseases 0.000 description 2
• 206010024305 Leukaemia monocytic Diseases 0.000 description 2
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
• 241000555688 Malassezia furfur Species 0.000 description 2
• 201000009906 Meningitis Diseases 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 2
• 102100021316 Mineralocorticoid receptor Human genes 0.000 description 2
• 208000034578 Multiple myelomas Diseases 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
• 206010062207 Mycobacterial infection Diseases 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 241000150452 Orthohantavirus Species 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 208000010191 Osteitis Deformans Diseases 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 208000027868 Paget disease Diseases 0.000 description 2
• 240000004371 Panax ginseng Species 0.000 description 2
• 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
• 235000003140 Panax quinquefolius Nutrition 0.000 description 2
• 208000031481 Pathologic Constriction Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 241000223960 Plasmodium falciparum Species 0.000 description 2
• 241000233872 Pneumocystis carinii Species 0.000 description 2
• 241001505332 Polyomavirus sp. Species 0.000 description 2
• 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 102100025803 Progesterone receptor Human genes 0.000 description 2
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
• 102000052575 Proto-Oncogene Human genes 0.000 description 2
• 108700020978 Proto-Oncogene Proteins 0.000 description 2
• 102000055251 Proto-Oncogene Proteins c-cbl Human genes 0.000 description 2
• 241000125945 Protoparvovirus Species 0.000 description 2
• 201000002154 Pterygium Diseases 0.000 description 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
• 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
• 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 2
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 2
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
• 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 2
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 208000017442 Retinal disease Diseases 0.000 description 2
• 206010038923 Retinopathy Diseases 0.000 description 2
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
• 241000223252 Rhodotorula Species 0.000 description 2
• 208000000705 Rift Valley Fever Diseases 0.000 description 2
• 102100022340 SHC-transforming protein 1 Human genes 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 241001523006 Talaromyces marneffei Species 0.000 description 2
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 description 2
• 206010057644 Testis cancer Diseases 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 208000024770 Thyroid neoplasm Diseases 0.000 description 2
• 101710183280 Topoisomerase Proteins 0.000 description 2
• 108010009583 Transforming Growth Factors Proteins 0.000 description 2
• 102000009618 Transforming Growth Factors Human genes 0.000 description 2
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
• 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 2
• 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 2
• 229910052770 Uranium Inorganic materials 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
• 208000014070 Vestibular schwannoma Diseases 0.000 description 2
• 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 2
• 241000235015 Yarrowia lipolytica Species 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 208000004064 acoustic neuroma Diseases 0.000 description 2
• 150000003973 alkyl amines Chemical class 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 108010080146 androgen receptors Proteins 0.000 description 2
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 244000309743 astrovirus Species 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 230000035578 autophosphorylation Effects 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
• 229940092714 benzenesulfonic acid Drugs 0.000 description 2
• NBXOPTAVRPDGNB-UHFFFAOYSA-N benzyl 5-bromo-2,4-bis(phenylmethoxy)benzoate Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(Br)=CC=1C(=O)OCC1=CC=CC=C1 NBXOPTAVRPDGNB-UHFFFAOYSA-N 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 206010006451 bronchitis Diseases 0.000 description 2
• 235000009120 camo Nutrition 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 230000022131 cell cycle Effects 0.000 description 2
• 230000025084 cell cycle arrest Effects 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 230000012292 cell migration Effects 0.000 description 2
• 230000010307 cell transformation Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 201000007455 central nervous system cancer Diseases 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 235000005607 chanvre indien Nutrition 0.000 description 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• 150000001924 cycloalkanes Chemical class 0.000 description 2
• 230000000120 cytopathologic effect Effects 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 229940121647 egfr inhibitor Drugs 0.000 description 2
• 235000013601 eggs Nutrition 0.000 description 2
• 229940116977 epidermal growth factor Drugs 0.000 description 2
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 108010038795 estrogen receptors Proteins 0.000 description 2
• 210000003414 extremity Anatomy 0.000 description 2
• 210000005002 female reproductive tract Anatomy 0.000 description 2
• 238000000855 fermentation Methods 0.000 description 2
• 201000003444 follicular lymphoma Diseases 0.000 description 2
• 235000020932 food allergy Nutrition 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 208000007565 gingivitis Diseases 0.000 description 2
• 235000008434 ginseng Nutrition 0.000 description 2
• 229940080856 gleevec Drugs 0.000 description 2
• 238000005469 granulation Methods 0.000 description 2
• 230000003179 granulation Effects 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 210000003128 head Anatomy 0.000 description 2
• 201000011066 hemangioma Diseases 0.000 description 2
• 239000011487 hemp Substances 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 208000002672 hepatitis B Diseases 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 150000004679 hydroxides Chemical class 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 230000001146 hypoxic effect Effects 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 208000017169 kidney disease Diseases 0.000 description 2
• 229940043355 kinase inhibitor Drugs 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 230000036210 malignancy Effects 0.000 description 2
• 208000027202 mammary Paget disease Diseases 0.000 description 2
• 201000006512 mast cell neoplasm Diseases 0.000 description 2
• 210000001595 mastoid Anatomy 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 102000006240 membrane receptors Human genes 0.000 description 2
• 108020004084 membrane receptors Proteins 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
• 201000006894 monocytic leukemia Diseases 0.000 description 2
• 208000027531 mycobacterial infectious disease Diseases 0.000 description 2
• 210000000066 myeloid cell Anatomy 0.000 description 2
• 208000001491 myopia Diseases 0.000 description 2
• 230000004379 myopia Effects 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 125000004433 nitrogen atom Chemical group N* 0.000 description 2
• 230000000414 obstructive effect Effects 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 230000002188 osteogenic effect Effects 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 2
• 108700009251 p80(NPM-ALK) Proteins 0.000 description 2
• 244000045947 parasite Species 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 208000028169 periodontal disease Diseases 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• 210000004214 philadelphia chromosome Anatomy 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
• 230000000704 physical effect Effects 0.000 description 2
• 201000011461 pre-eclampsia Diseases 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 108090000468 progesterone receptors Proteins 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 208000005069 pulmonary fibrosis Diseases 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 230000000241 respiratory effect Effects 0.000 description 2
• 208000023504 respiratory system disease Diseases 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• 229940081969 saccharomyces cerevisiae Drugs 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 231100000241 scar Toxicity 0.000 description 2
• 210000004116 schwann cell Anatomy 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical group C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 230000001568 sexual effect Effects 0.000 description 2
• 201000009890 sinusitis Diseases 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 230000036262 stenosis Effects 0.000 description 2
• 208000037804 stenosis Diseases 0.000 description 2
• 229940120982 tarceva Drugs 0.000 description 2
• 239000011975 tartaric acid Substances 0.000 description 2
• 235000002906 tartaric acid Nutrition 0.000 description 2
• 201000003120 testicular cancer Diseases 0.000 description 2
• 125000005942 tetrahydropyridyl group Chemical group 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 206010043778 thyroiditis Diseases 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 150000003852 triazoles Chemical class 0.000 description 2
• 230000005740 tumor formation Effects 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• KNXAMURPSBLVRZ-UHFFFAOYSA-N (decylamino)methanol Chemical compound CCCCCCCCCCNCO KNXAMURPSBLVRZ-UHFFFAOYSA-N 0.000 description 1
• WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• SHCFCJUJGBRSPO-UHFFFAOYSA-N 1-cyclohexylcyclohexan-1-amine Chemical compound C1CCCCC1C1(N)CCCCC1 SHCFCJUJGBRSPO-UHFFFAOYSA-N 0.000 description 1
• KVGOXGQSTGQXDD-UHFFFAOYSA-N 1-decane-sulfonic-acid Chemical compound CCCCCCCCCCS(O)(=O)=O KVGOXGQSTGQXDD-UHFFFAOYSA-N 0.000 description 1
• 125000006039 1-hexenyl group Chemical group 0.000 description 1
• 125000006023 1-pentenyl group Chemical group 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
• HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
• 125000006069 2,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
• 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• UPGATMBHQQONPH-UHFFFAOYSA-N 2-aminooxycarbonylbenzoic acid Chemical class NOC(=O)C1=CC=CC=C1C(O)=O UPGATMBHQQONPH-UHFFFAOYSA-N 0.000 description 1
• KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• 125000006040 2-hexenyl group Chemical group 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
• 125000005916 2-methylpentyl group Chemical group 0.000 description 1
• 125000006024 2-pentenyl group Chemical group 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
• 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• AHXQIXWOSLLMNU-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-methylindazol-6-yl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(S)=NN=2)C=2C=C3N(C)N=CC3=CC=2)=C1O AHXQIXWOSLLMNU-UHFFFAOYSA-N 0.000 description 1
• 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• USCSRAJGJYMJFZ-UHFFFAOYSA-N 3-methyl-1-butyne Chemical compound CC(C)C#C USCSRAJGJYMJFZ-UHFFFAOYSA-N 0.000 description 1
• 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000005917 3-methylpentyl group Chemical group 0.000 description 1
• FTTSHFLWYJBKGP-UHFFFAOYSA-N 4-(1,3-benzothiazol-6-yl)-3-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,4-triazole-5-thione Chemical compound C1=C(O)C(CC)=CC(C=2N(C(S)=NN=2)C=2C=C3SC=NC3=CC=2)=C1O FTTSHFLWYJBKGP-UHFFFAOYSA-N 0.000 description 1
• RITMIUOKLRJPJA-UHFFFAOYSA-N 4-(2-acetyl-1,3-dihydroisoindol-5-yl)-3-(2,4-dihydroxy-5-propan-2-ylphenyl)-1H-1,2,4-triazol-5-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3CN(CC3=CC=2)C(C)=O)=C1O RITMIUOKLRJPJA-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
• 241000224422 Acanthamoeba Species 0.000 description 1
• 241000922028 Acanthamoeba astronyxis Species 0.000 description 1
• 241000224423 Acanthamoeba castellanii Species 0.000 description 1
• 241000167877 Acanthamoeba culbertsoni Species 0.000 description 1
• 241000921991 Acanthamoeba hatchetti Species 0.000 description 1
• 241000224430 Acanthamoeba polyphaga Species 0.000 description 1
• 241001455958 Acanthamoeba rhysodes Species 0.000 description 1
• 208000010444 Acidosis Diseases 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 1
• 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
• 208000000884 Airway Obstruction Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 241000223602 Alternaria alternata Species 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 241000224489 Amoeba Species 0.000 description 1
• 206010002199 Anaphylactic shock Diseases 0.000 description 1
• 241000606646 Anaplasma Species 0.000 description 1
• 208000003120 Angiofibroma Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
• 241000712891 Arenavirus Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
• 200000000007 Arterial disease Diseases 0.000 description 1
• 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 241000228197 Aspergillus flavus Species 0.000 description 1
• 241001225321 Aspergillus fumigatus Species 0.000 description 1
• 241000351920 Aspergillus nidulans Species 0.000 description 1
• 241000228245 Aspergillus niger Species 0.000 description 1
• 241000203233 Aspergillus versicolor Species 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 208000023345 Autoimmune Diseases of the Nervous System Diseases 0.000 description 1
• 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 241000714235 Avian retrovirus Species 0.000 description 1
• 241000223836 Babesia Species 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 241000934146 Balamuthia mandrillaris Species 0.000 description 1
• 208000023514 Barrett esophagus Diseases 0.000 description 1
• 208000023665 Barrett oesophagus Diseases 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 208000035462 Biphenotypic Acute Leukemia Diseases 0.000 description 1
• 241000335423 Blastomyces Species 0.000 description 1
• 241000255789 Bombyx mori Species 0.000 description 1
• 208000006386 Bone Resorption Diseases 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 206010065553 Bone marrow failure Diseases 0.000 description 1
• 206010051779 Bone marrow toxicity Diseases 0.000 description 1
• 206010006002 Bone pain Diseases 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 235000000287 Brettanomyces bruxellensis Nutrition 0.000 description 1
• 241000722860 Brettanomyces naardenensis Species 0.000 description 1
• 206010006417 Bronchial carcinoma Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 210000003771 C cell Anatomy 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• RBKLSOKPXCBAIF-UHFFFAOYSA-N C1(=CC=CC2=CC=CC=C12)C(=O)O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O Chemical compound C1(=CC=CC2=CC=CC=C12)C(=O)O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O RBKLSOKPXCBAIF-UHFFFAOYSA-N 0.000 description 1
• 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 241000222173 Candida parapsilosis Species 0.000 description 1
• 241000512906 Candida solani Species 0.000 description 1
• 241001123652 Candida versatilis Species 0.000 description 1
• 235000002566 Capsicum Nutrition 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 208000009043 Chemical Burns Diseases 0.000 description 1
• 201000006082 Chickenpox Diseases 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
• 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
• 208000002691 Choroiditis Diseases 0.000 description 1
• 208000032544 Cicatrix Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 241000224483 Coccidia Species 0.000 description 1
• 241000223205 Coccidioides immitis Species 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• 241000709687 Coxsackievirus Species 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 201000007336 Cryptococcosis Diseases 0.000 description 1
• 241000221204 Cryptococcus neoformans Species 0.000 description 1
• 241000223936 Cryptosporidium parvum Species 0.000 description 1
• 108050006400 Cyclin Proteins 0.000 description 1
• 102000016736 Cyclin Human genes 0.000 description 1
• 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
• LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
• 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
• 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• 102000003915 DNA Topoisomerases Human genes 0.000 description 1
• 108090000323 DNA Topoisomerases Proteins 0.000 description 1
• 230000004543 DNA replication Effects 0.000 description 1
• 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 208000001490 Dengue Diseases 0.000 description 1
• 206010012310 Dengue fever Diseases 0.000 description 1
• 241000725619 Dengue virus Species 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 208000013558 Developmental Bone disease Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
• 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
• RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
• 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
• 208000030820 Ebola disease Diseases 0.000 description 1
• 241001115402 Ebolavirus Species 0.000 description 1
• 241000223932 Eimeria tenella Species 0.000 description 1
• 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
• 206010014612 Encephalitis viral Diseases 0.000 description 1
• 208000010334 End Stage Liver Disease Diseases 0.000 description 1
• 241000224432 Entamoeba histolytica Species 0.000 description 1
• 241000709661 Enterovirus Species 0.000 description 1
• 241000991587 Enterovirus C Species 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 241001480036 Epidermophyton floccosum Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 208000007985 Erythema Infectiosum Diseases 0.000 description 1
• 208000027776 Extrapyramidal disease Diseases 0.000 description 1
• 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 241000223221 Fusarium oxysporum Species 0.000 description 1
• 230000010190 G1 phase Effects 0.000 description 1
• 241000531123 GB virus C Species 0.000 description 1
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
• 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 241000224466 Giardia Species 0.000 description 1
• 241000224467 Giardia intestinalis Species 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 206010018498 Goitre Diseases 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 241000533386 Hansenia Species 0.000 description 1
• 241001149669 Hanseniaspora Species 0.000 description 1
• 241001149671 Hanseniaspora uvarum Species 0.000 description 1
• 244000286779 Hansenula anomala Species 0.000 description 1
• 235000014683 Hansenula anomala Nutrition 0.000 description 1
• 206010019143 Hantavirus pulmonary infection Diseases 0.000 description 1
• 208000001204 Hashimoto Disease Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
• 241000590002 Helicobacter pylori Species 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
• 241000711549 Hepacivirus C Species 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 208000005331 Hepatitis D Diseases 0.000 description 1
• 206010019773 Hepatitis G Diseases 0.000 description 1
• 208000037262 Hepatitis delta Diseases 0.000 description 1
• 241000724709 Hepatitis delta virus Species 0.000 description 1
• 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
• 102220553471 Hepatocyte growth factor receptor_Y1230D_mutation Human genes 0.000 description 1
• 102220553472 Hepatocyte growth factor receptor_Y1230H_mutation Human genes 0.000 description 1
• 241000709721 Hepatovirus A Species 0.000 description 1
• 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
• 208000004898 Herpes Labialis Diseases 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 240000001304 Hippeastrum striatum Species 0.000 description 1
• 241000228404 Histoplasma capsulatum Species 0.000 description 1
• 201000002563 Histoplasmosis Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
• 101000763352 Homo sapiens Heat shock protein 75 kDa, mitochondrial Proteins 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
• 101100291010 Homo sapiens MET gene Proteins 0.000 description 1
• 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
• 101000616502 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Proteins 0.000 description 1
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
• 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
• 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
• 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
• 241000829111 Human polyomavirus 1 Species 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 206010020649 Hyperkeratosis Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108030003815 Inositol 3-kinases Proteins 0.000 description 1
• 102100023915 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 241000701460 JC polyomavirus Species 0.000 description 1
• 201000005807 Japanese encephalitis Diseases 0.000 description 1
• 208000002260 Keloid Diseases 0.000 description 1
• 208000001126 Keratosis Diseases 0.000 description 1
• 241000235649 Kluyveromyces Species 0.000 description 1
• 244000285963 Kluyveromyces fragilis Species 0.000 description 1
• 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
• 241001138401 Kluyveromyces lactis Species 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
• 201000008197 Laryngitis Diseases 0.000 description 1
• 240000003483 Leersia hexandra Species 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 241000222727 Leishmania donovani Species 0.000 description 1
• 244000207740 Lemna minor Species 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 206010024264 Lethargy Diseases 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 206010025219 Lymphangioma Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 241000711828 Lyssavirus Species 0.000 description 1
• 201000003791 MALT lymphoma Diseases 0.000 description 1
• 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
• 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
• 101150024075 Mapk1 gene Proteins 0.000 description 1
• 208000000932 Marburg Virus Disease Diseases 0.000 description 1
• 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 1
• 241001115401 Marburgvirus Species 0.000 description 1
• 201000005505 Measles Diseases 0.000 description 1
• 241000712079 Measles morbillivirus Species 0.000 description 1
• 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 240000002624 Mespilus germanica Species 0.000 description 1
• 235000017784 Mespilus germanica Nutrition 0.000 description 1
• 241000893980 Microsporum canis Species 0.000 description 1
• 235000000560 Mimusops elengi Nutrition 0.000 description 1
• 241000712045 Morbillivirus Species 0.000 description 1
• 241000235395 Mucor Species 0.000 description 1
• 206010048723 Multiple-drug resistance Diseases 0.000 description 1
• 241000711386 Mumps virus Species 0.000 description 1
• 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
• 208000029549 Muscle injury Diseases 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
• 201000009623 Myopathy Diseases 0.000 description 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
• CKRUCMLSFJFOAI-UHFFFAOYSA-N NN.C1=CC=CC=2C3=CC=CC=C3CC12 Chemical compound NN.C1=CC=CC=2C3=CC=CC=C3CC12 CKRUCMLSFJFOAI-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 241000224438 Naegleria fowleri Species 0.000 description 1
• 208000000592 Nasal Polyps Diseases 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 206010029155 Nephropathy toxic Diseases 0.000 description 1
• 201000009053 Neurodermatitis Diseases 0.000 description 1
• 206010029350 Neurotoxicity Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 102000007999 Nuclear Proteins Human genes 0.000 description 1
• 108010089610 Nuclear Proteins Proteins 0.000 description 1
• RANGGRFKXIPVTL-UHFFFAOYSA-N OC1=CC(O)=CC=C1C1=NN=C(S)N1C1=CC=CC2=NC=CC=C12 Chemical compound OC1=CC(O)=CC=C1C1=NN=C(S)N1C1=CC=CC2=NC=CC=C12 RANGGRFKXIPVTL-UHFFFAOYSA-N 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 241000243985 Onchocerca volvulus Species 0.000 description 1
• 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
• 206010067152 Oral herpes Diseases 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 206010031252 Osteomyelitis Diseases 0.000 description 1
• 208000008558 Osteophyte Diseases 0.000 description 1
• 206010033078 Otitis media Diseases 0.000 description 1
• 108091008606 PDGF receptors Proteins 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
• 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 101710161551 Pectate lyase 3 Proteins 0.000 description 1
• 241000237503 Pectinidae Species 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 239000006002 Pepper Substances 0.000 description 1
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 241000132157 Phacochoerus africanus Species 0.000 description 1
• 241000713137 Phlebovirus Species 0.000 description 1
• 102100021797 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Human genes 0.000 description 1
• 101710124951 Phospholipase C Proteins 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• 241000521553 Pichia fermentans Species 0.000 description 1
• 241000235645 Pichia kudriavzevii Species 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
• 235000011613 Pinus brutia Nutrition 0.000 description 1
• 241000018646 Pinus brutia Species 0.000 description 1
• 235000016761 Piper aduncum Nutrition 0.000 description 1
• 240000003889 Piper guineense Species 0.000 description 1
• 235000017804 Piper guineense Nutrition 0.000 description 1
• 235000008184 Piper nigrum Nutrition 0.000 description 1
• 241000224017 Plasmodium berghei Species 0.000 description 1
• 241000223821 Plasmodium malariae Species 0.000 description 1
• 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
• 241000223810 Plasmodium vivax Species 0.000 description 1
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 208000008601 Polycythemia Diseases 0.000 description 1
• 208000003971 Posterior uveitis Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 206010036590 Premature baby Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• 101710179609 Probable pectin lyase C Proteins 0.000 description 1
• 206010036877 Prolonged Pregnancy Diseases 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 108010026552 Proteome Proteins 0.000 description 1
• 102000005663 Proto-Oncogene Proteins c-abl Human genes 0.000 description 1
• 108010045292 Proto-Oncogene Proteins c-abl Proteins 0.000 description 1
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
• ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
• 101150090155 R gene Proteins 0.000 description 1
• 206010037742 Rabies Diseases 0.000 description 1
• 241000711798 Rabies lyssavirus Species 0.000 description 1
• 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 241000702263 Reovirus sp. Species 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 241000725643 Respiratory syncytial virus Species 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• 206010038848 Retinal detachment Diseases 0.000 description 1
• 206010038910 Retinitis Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 108050002653 Retinoblastoma protein Proteins 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
• 241000713124 Rift Valley fever virus Species 0.000 description 1
• 239000008156 Ringer's lactate solution Substances 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 241000710799 Rubella virus Species 0.000 description 1
• 241000235072 Saccharomyces bayanus Species 0.000 description 1
• 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
• 241000582914 Saccharomyces uvarum Species 0.000 description 1
• 241001439627 Schistostoma Species 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 206010039705 Scleritis Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 201000001880 Sexual dysfunction Diseases 0.000 description 1
• 206010049771 Shock haemorrhagic Diseases 0.000 description 1
• 206010072610 Skeletal dysplasia Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010040829 Skin discolouration Diseases 0.000 description 1
• 208000032140 Sleepiness Diseases 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 206010041349 Somnolence Diseases 0.000 description 1
• 241000589970 Spirochaetales Species 0.000 description 1
• 241001149962 Sporothrix Species 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
• 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
• 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
• 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
• 208000025371 Taste disease Diseases 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• 241000270666 Testudines Species 0.000 description 1
• 241000223777 Theileria Species 0.000 description 1
• 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 208000001435 Thromboembolism Diseases 0.000 description 1
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
• 241000235006 Torulaspora Species 0.000 description 1
• 206010044221 Toxic encephalopathy Diseases 0.000 description 1
• 241000223996 Toxoplasma Species 0.000 description 1
• 241000223997 Toxoplasma gondii Species 0.000 description 1
• 201000005485 Toxoplasmosis Diseases 0.000 description 1
• 101710204707 Transforming growth factor-beta receptor-associated protein 1 Proteins 0.000 description 1
• 241000243777 Trichinella spiralis Species 0.000 description 1
• 241000224526 Trichomonas Species 0.000 description 1
• 241000224527 Trichomonas vaginalis Species 0.000 description 1
• 241001459572 Trichophyton interdigitale Species 0.000 description 1
• 241000223229 Trichophyton rubrum Species 0.000 description 1
• 241000223231 Trichosporon beigelii Species 0.000 description 1
• 241000223104 Trypanosoma Species 0.000 description 1
• 241001442399 Trypanosoma brucei gambiense Species 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 206010046788 Uterine haemorrhage Diseases 0.000 description 1
• 235000007837 Vangueria infausta Nutrition 0.000 description 1
• 206010046980 Varicella Diseases 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 208000024248 Vascular System injury Diseases 0.000 description 1
• 208000012339 Vascular injury Diseases 0.000 description 1
• 206010053648 Vascular occlusion Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 101150030763 Vegfa gene Proteins 0.000 description 1
• 206010058990 Venous occlusion Diseases 0.000 description 1
• 206010047663 Vitritis Diseases 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 208000013058 Weber syndrome Diseases 0.000 description 1
• 208000003152 Yellow Fever Diseases 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 241000235033 Zygosaccharomyces rouxii Species 0.000 description 1
• RROJYLNOPDVWGW-UHFFFAOYSA-N [2-ethyl-5-hydroxy-4-(4-naphthalen-2-yl-5-oxo-1H-1,2,4-triazol-3-yl)phenyl] N,N-dimethylcarbamate Chemical compound OC1=C(C=C(C(=C1)OC(N(C)C)=O)CC)C1=NN=C(N1C1=CC2=CC=CC=C2C=C1)O RROJYLNOPDVWGW-UHFFFAOYSA-N 0.000 description 1
• 241000222126 [Candida] glabrata Species 0.000 description 1
• 241000191335 [Candida] intermedia Species 0.000 description 1
• 241000192286 [Candida] stellata Species 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 230000007950 acidosis Effects 0.000 description 1
• 208000026545 acidosis disease Diseases 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 208000009621 actinic keratosis Diseases 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 238000001467 acupuncture Methods 0.000 description 1
• 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 239000000809 air pollutant Substances 0.000 description 1
• 231100001243 air pollutant Toxicity 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 208000030961 allergic reaction Diseases 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 125000006242 amine protecting group Chemical group 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 208000000252 angiomatosis Diseases 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 230000002547 anomalous effect Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 208000021328 arterial occlusion Diseases 0.000 description 1
• 230000005744 arteriovenous malformation Effects 0.000 description 1
• 206010003230 arteritis Diseases 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 229940091771 aspergillus fumigatus Drugs 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 230000003416 augmentation Effects 0.000 description 1
• 208000035362 autoimmune disorder of the nervous system Diseases 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 201000004339 autoimmune neuropathy Diseases 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 230000004900 autophagic degradation Effects 0.000 description 1
• 201000008680 babesiosis Diseases 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 229910001570 bauxite Inorganic materials 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• RQDRYTQXKFCWDT-UHFFFAOYSA-N benzoic acid;1,3-dioxolane Chemical compound C1COCO1.OC(=O)C1=CC=CC=C1 RQDRYTQXKFCWDT-UHFFFAOYSA-N 0.000 description 1
• 239000012964 benzotriazole Substances 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 231100000366 bone marrow toxicity Toxicity 0.000 description 1
• 230000024279 bone resorption Effects 0.000 description 1
• 101150048834 braF gene Proteins 0.000 description 1
• 201000007293 brain stem infarction Diseases 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 239000012267 brine Substances 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
• 229940095731 candida albicans Drugs 0.000 description 1
• 208000032343 candida glabrata infection Diseases 0.000 description 1
• 229940055022 candida parapsilosis Drugs 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• 238000000633 chiral stationary phase gas chromatography Methods 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 208000011444 chronic liver failure Diseases 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• 210000004240 ciliary body Anatomy 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 229940126214 compound 3 Drugs 0.000 description 1
• 210000000795 conjunctiva Anatomy 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 206010011005 corneal dystrophy Diseases 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
• URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical compound C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 description 1
• 239000004913 cyclooctene Substances 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 208000025729 dengue disease Diseases 0.000 description 1
• 208000002925 dental caries Diseases 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 208000024558 digestive system cancer Diseases 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 206010013781 dry mouth Diseases 0.000 description 1
• 230000008143 early embryonic development Effects 0.000 description 1
• 235000013399 edible fruits Nutrition 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 210000003372 endocrine gland Anatomy 0.000 description 1
• 206010014801 endophthalmitis Diseases 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 229940007078 entamoeba histolytica Drugs 0.000 description 1
• 230000029578 entry into host Effects 0.000 description 1
• 230000006353 environmental stress Effects 0.000 description 1
• 239000003256 environmental substance Substances 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• WILVYLQMYNGFSH-UHFFFAOYSA-N ethanamine;n-ethylethanamine Chemical compound CCN.CCNCC WILVYLQMYNGFSH-UHFFFAOYSA-N 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 201000010934 exostosis Diseases 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 208000024711 extrinsic asthma Diseases 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 239000003337 fertilizer Substances 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 206010016629 fibroma Diseases 0.000 description 1
• 206010049444 fibromatosis Diseases 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• WTDFFADXONGQOM-UHFFFAOYSA-N formaldehyde;hydrochloride Chemical compound Cl.O=C WTDFFADXONGQOM-UHFFFAOYSA-N 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
• 201000010231 gastrointestinal system cancer Diseases 0.000 description 1
• 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 102000034356 gene-regulatory proteins Human genes 0.000 description 1
• 108091006104 gene-regulatory proteins Proteins 0.000 description 1
• 210000004392 genitalia Anatomy 0.000 description 1
• 231100000024 genotoxic Toxicity 0.000 description 1
• 230000001738 genotoxic effect Effects 0.000 description 1
• 229940114119 gentisate Drugs 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 229940097042 glucuronate Drugs 0.000 description 1
• 229940097043 glucuronic acid Drugs 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
• 201000003872 goiter Diseases 0.000 description 1
• 210000002149 gonad Anatomy 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 101150098203 grb2 gene Proteins 0.000 description 1
• 210000004884 grey matter Anatomy 0.000 description 1
• VNSFGLSIVSOPEC-UHFFFAOYSA-N guanidine;urea Chemical compound NC(N)=N.NC(N)=O VNSFGLSIVSOPEC-UHFFFAOYSA-N 0.000 description 1
• 208000024963 hair loss Diseases 0.000 description 1
• 230000003676 hair loss Effects 0.000 description 1
• 235000015220 hamburgers Nutrition 0.000 description 1
• 201000005648 hantavirus pulmonary syndrome Diseases 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 208000025750 heavy chain disease Diseases 0.000 description 1
• 229940037467 helicobacter pylori Drugs 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 230000009033 hematopoietic malignancy Effects 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• 201000010284 hepatitis E Diseases 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 208000013653 hyalitis Diseases 0.000 description 1
• 150000007857 hydrazones Chemical class 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 231100000619 immunotoxicology Toxicity 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 229940060367 inert ingredients Drugs 0.000 description 1
• 208000013256 infectious meningitis Diseases 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 239000002085 irritant Substances 0.000 description 1
• 231100000021 irritant Toxicity 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 239000009004 jinqing Substances 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
• 210000001117 keloid Anatomy 0.000 description 1
• 201000010666 keratoconjunctivitis Diseases 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 201000002364 leukopenia Diseases 0.000 description 1
• 231100001022 leukopenia Toxicity 0.000 description 1
• 208000002741 leukoplakia Diseases 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
• 201000003265 lymphadenitis Diseases 0.000 description 1
• 208000012804 lymphangiosarcoma Diseases 0.000 description 1
• 210000001077 lymphatic endothelium Anatomy 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 230000010311 mammalian development Effects 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 229960003151 mercaptamine Drugs 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229910000000 metal hydroxide Inorganic materials 0.000 description 1
• 150000004692 metal hydroxides Chemical class 0.000 description 1
• 235000019656 metallic taste Nutrition 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• VNXBKJFUJUWOCW-UHFFFAOYSA-N methylcyclopropane Chemical compound CC1CC1 VNXBKJFUJUWOCW-UHFFFAOYSA-N 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 238000003032 molecular docking Methods 0.000 description 1
• 229940057059 monascus purpureus Drugs 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 201000000626 mucocutaneous leishmaniasis Diseases 0.000 description 1
• 230000036457 multidrug resistance Effects 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 208000013465 muscle pain Diseases 0.000 description 1
• 208000017445 musculoskeletal system disease Diseases 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 210000001087 myotubule Anatomy 0.000 description 1
• 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 201000003142 neovascular glaucoma Diseases 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• 230000007694 nephrotoxicity Effects 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 231100000228 neurotoxicity Toxicity 0.000 description 1
• 230000007135 neurotoxicity Effects 0.000 description 1
• 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 108091008569 nuclear steroid hormone receptors Proteins 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 208000002042 onchocerciasis Diseases 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 230000005305 organ development Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000011164 ossification Effects 0.000 description 1
• 229940127084 other anti-cancer agent Drugs 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 208000025661 ovarian cyst Diseases 0.000 description 1
• 150000003901 oxalic acid esters Chemical class 0.000 description 1
• AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
• 230000020477 pH reduction Effects 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229940014662 pantothenate Drugs 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
• 201000010198 papillary carcinoma Diseases 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000009589 pathological growth Effects 0.000 description 1
• 201000002689 pediatric hepatocellular carcinoma Diseases 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• 201000001245 periodontitis Diseases 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical class N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
• 230000037081 physical activity Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 102000002022 plexin Human genes 0.000 description 1
• 108050009312 plexin Proteins 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
• 230000007757 pro-survival signaling Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 210000004765 promyelocyte Anatomy 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000004063 proteosomal degradation Effects 0.000 description 1
• 208000028172 protozoa infectious disease Diseases 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 230000010349 pulsation Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 125000001725 pyrenyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 229960001285 quercetin Drugs 0.000 description 1
• 235000005875 quercetin Nutrition 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 108010077182 raf Kinases Proteins 0.000 description 1
• 102000009929 raf Kinases Human genes 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 210000001350 reed-sternberg cell Anatomy 0.000 description 1
• 230000022021 regulation of cell morphogenesis Effects 0.000 description 1
• 230000025053 regulation of cell proliferation Effects 0.000 description 1
• 201000010174 renal carcinoma Diseases 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 230000004264 retinal detachment Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 102220198013 rs1057519824 Human genes 0.000 description 1
• 102220197908 rs121913244 Human genes 0.000 description 1
• 102220004853 rs121913246 Human genes 0.000 description 1
• 102220067223 rs121913247 Human genes 0.000 description 1
• 102220004851 rs121913670 Human genes 0.000 description 1
• 102220004854 rs121913673 Human genes 0.000 description 1
• 102220004856 rs121913676 Human genes 0.000 description 1
• 102220004857 rs121913677 Human genes 0.000 description 1
• 229960002181 saccharomyces boulardii Drugs 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 235000020637 scallop Nutrition 0.000 description 1
• 230000037387 scars Effects 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 208000018964 sebaceous gland cancer Diseases 0.000 description 1
• 230000001235 sensitizing effect Effects 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 231100000872 sexual dysfunction Toxicity 0.000 description 1
• 235000015170 shellfish Nutrition 0.000 description 1
• 201000006476 shipyard eye Diseases 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 230000037370 skin discoloration Effects 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 230000001148 spastic effect Effects 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000021595 spermatogenesis Effects 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 208000037959 spinal tumor Diseases 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 102000005969 steroid hormone receptors Human genes 0.000 description 1
• 108020003113 steroid hormone receptors Proteins 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000004575 stone Substances 0.000 description 1
• 210000000434 stratum corneum Anatomy 0.000 description 1
• 125000005415 substituted alkoxy group Chemical group 0.000 description 1
• 229940086735 succinate Drugs 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 230000004654 survival pathway Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• 201000008753 synovium neoplasm Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 208000006379 syphilis Diseases 0.000 description 1
• 229940066765 systemic antihistamines substituted ethylene diamines Drugs 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• TYYCBAISLMKLMT-UHFFFAOYSA-N tert-butyl 3-amino-3-phenylpropanoate Chemical compound CC(C)(C)OC(=O)CC(N)C1=CC=CC=C1 TYYCBAISLMKLMT-UHFFFAOYSA-N 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 150000004685 tetrahydrates Chemical class 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 125000003944 tolyl group Chemical group 0.000 description 1
• 206010044008 tonsillitis Diseases 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 description 1
• IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
• 229940096911 trichinella spiralis Drugs 0.000 description 1
• 229960001124 trientine Drugs 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 150000004684 trihydrates Chemical class 0.000 description 1
• 150000003648 triterpenes Chemical class 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 230000005748 tumor development Effects 0.000 description 1
• 239000000225 tumor suppressor protein Substances 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 230000036269 ulceration Effects 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 208000037965 uterine sarcoma Diseases 0.000 description 1
• 208000021331 vascular occlusion disease Diseases 0.000 description 1
• 239000004066 vascular targeting agent Substances 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 201000002498 viral encephalitis Diseases 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 206010047470 viral myocarditis Diseases 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 108700026215 vpr Genes Proteins 0.000 description 1
• 238000013389 whole blood assay Methods 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1